BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 2887615)

  • 1. Famotidine: effective treatment of Zollinger-Ellison syndrome.
    Howard JM; Vinayek R; Maton PN; Wank SA; Gardner JD; Jensen RT
    J Clin Gastroenterol; 1987; 9 Suppl 2():23-5. PubMed ID: 2887615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome.
    Howard JM; Chremos AN; Collen MJ; McArthur KE; Cherner JA; Maton PN; Ciarleglio CA; Cornelius MJ; Gardner JD; Jensen RT
    Gastroenterology; 1985 Apr; 88(4):1026-33. PubMed ID: 2857672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Famotidine in the therapy of gastric hypersecretory states.
    Vinayek R; Howard JM; Maton PN; Wank SA; Slaff JI; Gardner JD; Jensen RT
    Am J Med; 1986 Oct; 81(4B):49-59. PubMed ID: 2877575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parenteral control of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Vinayek R; Hahne WF; Euler AR; Norton JA; Jensen RT
    Dig Dis Sci; 1993 Oct; 38(10):1857-65. PubMed ID: 8104773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in the management of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Maton PN; Gardner JD; Jensen RT
    Gastroenterol Clin North Am; 1989 Dec; 18(4):847-63. PubMed ID: 2575602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome.
    Campoli-Richards DM; Clissold SP
    Drugs; 1986 Sep; 32(3):197-221. PubMed ID: 2875864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of famotidine with cimetidine and ranitidine.
    Berardi RR; Tankanow RM; Nostrant TT
    Clin Pharm; 1988 Apr; 7(4):271-84. PubMed ID: 2896559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Famotidine. The ACG Committee on FDA-Related Matters with primary authorship by G. Friedman. American College of Gastroenterology.
    Am J Gastroenterol; 1987 Jun; 82(6):504-6. PubMed ID: 2883885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [24-hour intragastric acid profile in a ZES patient with H2 blockers].
    Dammann HG; Müller P; Simon B; Kommerell B
    Z Gastroenterol; 1984 Jun; 22(6):318-20. PubMed ID: 6147052
    [No Abstract]   [Full Text] [Related]  

  • 10. Parenteral antisecretory drug therapy in patients with Zollinger-Ellison syndrome.
    Saeed ZA; Norton JA; Frank WO; Young MD; Maton PN; Gardner JD; Jensen RT
    Gastroenterology; 1989 Jun; 96(6):1393-402. PubMed ID: 2565842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of acid suppressants in patients with Zollinger-Ellison syndrome.
    Maton PN
    Aliment Pharmacol Ther; 1991; 5 Suppl 1():25-35. PubMed ID: 1679671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of ranitidine and cimetidine in the treatment of gastric hypersecretion.
    Collen MJ; Howard JM; McArthur KE; Raufman JP; Cornelius MJ; Ciarleglio CA; Gardner JD; Jensen RT
    Ann Intern Med; 1984 Jan; 100(1):52-8. PubMed ID: 6318628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Zollinger-Ellison syndrome with exploratory laparotomy, proximal gastric vagotomy, and H2-receptor antagonists. A prospective study.
    Richardson CT; Peters MN; Feldman M; McClelland RN; Walsh JH; Cooper KA; Willeford G; Dickerman RM; Fordtran JS
    Gastroenterology; 1985 Aug; 89(2):357-67. PubMed ID: 2861140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effectiveness of ranitidine and cimetidine in inhibiting acid secretion in patients with gastric hypersecretory states.
    Jensen RT; Collen MJ; McArthur KE; Howard JM; Maton PN; Cherner JA; Gardner JD
    Am J Med; 1984 Nov; 77(5B):90-105. PubMed ID: 6150641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ranitidine and cimetidine in Zollinger-Ellison syndrome.
    Mignon M; Vallot T; Mayeur S; Bonfils S
    Br J Clin Pharmacol; 1980 Aug; 10(2):173-4. PubMed ID: 6107118
    [No Abstract]   [Full Text] [Related]  

  • 16. [A case of refractory chronic Zollinger-Ellison syndrome--treated successfully with famotidine].
    Shiratori K; Watanabe S; Maruyama M; Adachi H; Itoh Y; Kurokawa K; Takeuchi T
    Nihon Shokakibyo Gakkai Zasshi; 1984 Jul; 81(7):1623-7. PubMed ID: 6149326
    [No Abstract]   [Full Text] [Related]  

  • 17. [The role of H2 antagonists in Zollinger-Ellison syndrome].
    Dammann HG; Walter TA; Müller P; Simon B
    Clin Ter; 1984 Dec; 111(5):393-400. PubMed ID: 6151434
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacology and clinical efficacy of ranitidine, a new H2-receptor antagonist.
    Helman CA; Tim LO
    Pharmacotherapy; 1983; 3(4):185-92. PubMed ID: 6136952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome.
    Pisegna JR; Norton JA; Slimak GG; Metz DC; Maton PN; Gardner JD; Jensen RT
    Gastroenterology; 1992 Mar; 102(3):767-78. PubMed ID: 1537514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of omeprazole in seven patients with Zollinger-Ellison syndrome resistant to histamine H2-receptor antagonists.
    Delchier JC; Soule JC; Mignon M; Goldfain D; Cortot A; Travers B; Isal JP; Bader JP
    Dig Dis Sci; 1986 Jul; 31(7):693-9. PubMed ID: 2873001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.